Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 5/2019

01-05-2019 | Alzheimer's Disease | Original Research Article

Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer’s Disease: A Network Meta-Analysis

Authors: Onnita Thancharoen, Chulaporn Limwattananon, Onanong Waleekhachonloet, Thananan Rattanachotphanit, Phumtham Limwattananon, Panita Limpawattana

Published in: Drugs & Aging | Issue 5/2019

Login to get access

Abstract

Background

Cholinesterase inhibitors (ChEIs) and memantine have been reported to provide modest benefits for cognition and aspects of functioning in Alzheimer’s disease (AD). Ginkgo biloba extract (EGb761), a phytomedicine, is widely used and expected to be well-tolerated. A few trials have compared EGb761 with ChEIs, and the results were inconclusive.

Objective

A network meta-analysis was conducted to evaluate the therapeutic benefits and tolerability of EGb761, three ChEIs (donepezil, galantamine, and rivastigmine), and memantine in mild-to-moderate AD patients.

Methods

Electronic databases were searched through 30 June 2017. We included randomized double-blinded trials with a minimum treatment duration of 22 weeks for EGb761 240 mg/day and 12 weeks for ChEIs or memantine. The study patients included AD or probable AD patients without other types of dementia or neurological disorders. Cognition, function, and behavior symptoms were compared between treatments using the standardized mean difference (SMD). Clinical global impression, treatment discontinuation, and adverse events were compared between treatments using the relative risk (RR). Statistical pooling of the individual trial results was conducted using a frequentist approach. The probability of being the best for a treatment was estimated using surface under the cumulative ranking.

Results

EGb761 and memantine showed no therapeutic benefits in all study outcomes. For cognition, all ChEIs were significantly better than placebo (SMD from − 0.52 to − 0.26), and galantamine was better than rivastigmine in the oral and patch forms, EGb761, and memantine (SMD [95% confidence interval (CI)]: − 0.22 [− 0.40 to − 0.05]; − 0.26 [− 0.45 to − 0.07]; − 0.34 [− 0.56 to −  0.12]; and − 0.42 [− 0.71 to − 0.13], respectively). Compared to placebo, galantamine, the rivastigmine patch, and oral rivastigmine provided modest functional benefits (SMD, from 0.21 to 0.24), and galantamine provided behavioral benefits (SMD [95% CI]: − 0.15 [− 0.26 to − 0.04]). All ChEIs provided a better improvement in clinical global impression than placebo (RR from 1.20 to 1.69). The global impression ratings were more improved with donepezil than with galantamine (RR [95% CI]: 1.40 [1.09–1.80]) or with EGb761 (RR [95% CI]: 1.40 [1.06–1.85]), with a 96% probability of donepezil being more effective than the other study agents. Rivastigmine in oral and patch forms, galantamine, and donepezil had a higher risk of being discontinued than placebo (RR [95% CI]: 2.14 [1.49–3.06]; 2.04 [1.30–3.20]; 1.79 [1.28–2.49]; 1.49 [1.03–2.17], respectively). Discontinuation of EGb761 was not statistically lower than that of the ChEIs, in which donepezil had the lowest probability (38%) of being discontinued.

Conclusion

EGb761 and memantine showed no treatment benefits compared to placebo and ChEIs. Galantamine provided the highest beneficial effect on cognition and behavioral symptoms. Donepezil provided a better clinical global impression and tolerability than the other ChEIs and EGb761, with a similar benefit for cognition as galantamine.
Appendix
Available only for authorised users
Literature
1.
2.
Prince M, Wimo AGM, Ali GC, Wu YT, Prina M. World Alzheimer report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease International; 2015.
3.
Ngo J, Holroyd-Leduc J. Systematic review of recent dementia practice guidelines. Age Ageing. 2014;44:25–33.CrossRefPubMed
4.
5.
Lang F, Hoerr R, Noeldner M, Koch E. Ginkgo biloba extract EGb 761: from an ancient Asian plant to a modern European herbal medicinal product. In: Wagner H, Ulrich-Merzenich G, editors. Evidence and rational based research on Chinese drugs. Wien: Springer; 2013. p. 431–70.CrossRef
6.
7.
Jeschke E, Ostermann T, Vollmar H, Tabali M, Schad F, Matthes H. Prescribing patterns in dementia: a multicentre observational study in a German network of CAM physicians. BMC Neurol. 2011;11:1–11.CrossRef
8.
Czeche S, Schussel K, Franzmann A, Burkart M, Schulz M. Dosage strength is associated with medication persistence with Ginkgo biloba drug products: a cohort study of ambulatory drug claims data in Germany. BMC Complement Altern Med. 2013;13:1–10.CrossRef
9.
Stein C, Hopfeld J, Lau H, Klein J. Effects of Ginkgo biloba extract EGb761, donepezil and their combination on central cholinergic function in aged rats. J Pharm Pharm Sci. 2015;18:634–46.CrossRefPubMed
10.
11.
Gauthier S, Schlaefke S. Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interv Aging. 2014;9:2065–77.CrossRefPubMedPubMedCentral
12.
Tan M, Yu J, Tan C, et al. Efficacy and adverse effects of Ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2015;43:589–603.CrossRefPubMed
13.
von Gunten A, Schlaefke S, Uberla K. Efficacy of Ginkgo biloba extract EGb761® in dementia with behavioural and psychological symptoms: a systematic review. World J Biol Psychiatry. 2015;17:622–33.CrossRef
14.
Yuan Q, Wang CW, Shi J, Lin ZX. Effects of Ginkgo biloba on dementia: an overview of systematic reviews. J Ethnopharmacol. 2017;195:1–9.CrossRefPubMed
15.
Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo-controlled double-blind study. Eur J Paediatr Neurol. 2006;13:981–5.CrossRef
16.
Nasab NM, Bahrammi MA, Nikpour MR, Rahim F, Naghibis SN. Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer’s dementia. J Pak Med Assoc. 2012;62(7):677–80.PubMed
17.
Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke S, Hoerr R. Ginkgo biloba extract EGb761®, donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomized, double-blind, exploratory trial. Aging Ment Health. 2009;13:183–90.CrossRefPubMed
18.
Di Santo S, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer’s disease. J Alzheimers Dis. 2013;35:349–61.CrossRefPubMed
19.
Tan C, Yu J, Wang H, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41:615–31.CrossRefPubMed
20.
Kobayashi H, Ohnishi T, Nakagawa R, Yoshizawa K. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: a Bayesian network meta-analysis. Int J Geriatr Psychiatry. 2015;31:892–904.CrossRefPubMedPubMedCentral
21.
Tricco A, Ashoor H, Soobiah C, et al. Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer’s disease: systematic review and network meta-analysis. J Am Geriatr Soc. 2017;66:170–8.CrossRefPubMed
22.
Deardorff WJ, Feen E, Grossberg GT. The use of cholinesterase inhibitors across all stages of Alzheimer’s disease. Drugs Aging. 2015;32(7):537–47.CrossRefPubMed
23.
24.
25.
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984;141:1356–64.CrossRefPubMed
26.
Cano S, Posner H, Moline M, et al. The ADAS-cog in Alzheimer’s disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry. 2010;81:1363–8.CrossRefPubMed
27.
Rockwood K, Fay S, Gorman M. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer’s disease. Int J Geriatr Psychiatry. 2010;25:191–201.CrossRefPubMed
28.
Kanowski S, Hoerr R. Ginkgo biloba extract EGb761® in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2003;36:297–303.CrossRefPubMed
29.
Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S. Ginkgo biloba extract EGb761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. Psychiatry Res. 2012;46:716–23.CrossRef
30.
Ihl R, Tribanek M, Bachinskaya N. Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb761® in Alzheimer’s disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry. 2012;45:41–6.CrossRefPubMed
31.
Ihl R, Grass-Kapanke B, Janner M, Weyer G. Neuropsychometric tests in cross sectional and longitudinal studies-a regression analysis of ADAS-Cog, SKT and MMSE. Pharmacopsychiatry. 1999;32:248–54.CrossRefPubMed
32.
Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimerʼs disease. Alzheimer Dis Assoc Disord. 1997;11:33–9.CrossRef
33.
Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer’s disease: the Disability Assessment for Dementia. Am J Occup Ther. 1999;53:471–81.CrossRefPubMed
34.
Cummings J, Mega M, Gray K, Rosenberg-Thompson S, Carusi D, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–14.CrossRefPubMed
35.
Cummings J. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:S10–6.CrossRefPubMed
36.
Olin J, Schneider L, Doody R, et al. Clinical evaluation of global change in Alzheimer’s disease: identifying consensus. J Geriatr Psychiatry Neurol. 1996;9:176–80.CrossRefPubMed
37.
Reisberg B. Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatr. 2007;19:421–56.CrossRefPubMed
38.
Schneider L, Olin J, Doody R, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord. 1997;2:22s–32s.CrossRef
39.
Nakamura Y, Usui M, Nishikawa T, et al. CIBIC Plus-J assessment using a videotaped method in Alzheimer’s disease patients. Dement Geriatr Cogn Disord Extra. 2011;2:271–7.CrossRef
40.
White IR. Multivariate random-effects meta-analysis. Stata J. 2009;9:40–56.CrossRef
41.
White IR. Multivariate random-effects meta-regression: updates to mvmeta. Stata J. 2011;11:255–70.CrossRef
42.
43.
White IR, Barrett JK, Jackson D, Higgins J. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3:111–25.CrossRefPubMedPubMedCentral
44.
Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29:932–44.CrossRefPubMed
45.
Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163–71.CrossRefPubMed
46.
Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res. 2005;2:541–51.CrossRefPubMed
47.
Rogers SL, Doody RS, Mohs RC, Friendhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158:1021–31.CrossRefPubMed
48.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friendhoff LT. A 24-week, double-blind, placebo controlled trial of donepezil in patients with Alzheimer’s disease. Neurology. 1998;50:136–45.CrossRefPubMed
49.
Burn A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease—results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237–44.CrossRef
50.
Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. Dement Geriatr Cogn Disord. 2000;11:299–313.CrossRefPubMed
51.
Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2010;26:536–44.CrossRefPubMed
52.
Frölich L, Ashwood T, Nilsson J, Eckerwall G, Sirocco Investigator. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer’s disease: a phase IIb dose-finding study. J Alzheimers Dis. 2011;24:363–74.CrossRefPubMed
53.
Zhang Z, Yu L, Gaudig M, Schauble B, Richarz U. Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study. Neuropsychiatr Dis Treat. 2012;8:571–7.PubMedPubMedCentral
54.
Marek GJ, Katz DA, Meier A, et al. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer’s disease. Alzheimers Dement. 2014;10:S364–73.CrossRefPubMed
55.
Haig GM, Pritchett Y, Meier A, et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer’s dementia. J Alzheimers Dis. 2014;42:959–71.CrossRefPubMed
56.
Gault L, Ritchie C, Robieson W, Pritchett Y, Othman A, Lenz R. A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer’s dementia. Alzheimers Dement (NY). 2015;1:81–90.
57.
Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261–8.CrossRefPubMed
58.
Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54:2269–76.CrossRefPubMed
59.
Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ. 2000;9:1445–9.CrossRef
60.
Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease. Int J Geriatr Psychiatry. 2001;16:852–7.CrossRefPubMed
61.
Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord. 2005;20:120–32.CrossRefPubMed
62.
Rockwood K, Fay S, Song X, Macknight C, Gorman M, Video-Imaging Synthesis of Treating Alzheimer’s Disease (VISTA) Investigators. Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial. CMAJ. 2006;174:1099–105.CrossRefPubMedPubMedCentral
63.
Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychiatry. 1998;1:55–65.
64.
Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ. 1999;318:633–8.CrossRefPubMedPubMedCentral
65.
Feldman HH, Lane R. Rivastigmine: a placebo-controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2007;78:1056–63.CrossRefPubMedPubMedCentral
66.
Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22:456–67.CrossRefPubMed
67.
Nakamura Y, Imai Y, Shigeta M, et al. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2011;1:163–79.CrossRefPubMedPubMedCentral
68.
Zhang ZX, Hong Z, Wang YP, et al. Rivastigmine patch in Chinese patients with probable Alzheimer’s disease: a 24-week, randomized, double-blind parallel-group study comparing rivastigmine patch (9.5 mg/24 h) with capsule (6 mg twice daily). CNS Neurosci Ther. 2016;22:488–96.CrossRefPubMedPubMedCentral
69.
Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2007;11:471–9.CrossRefPubMed
70.
Hashiguchi M, Ohta Y, Shimizu M, Maruyama J, Mochizuki M. Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia. J Pharm Health Care Sci. 2015;1:1–12.CrossRef
71.
Strohle A, Schmidt DK, Schultz F, et al. Drug and exercise treatment of Alzheimer disease and mild cognitive impairment: a systematic review and meta-analysis of effects on cognition in randomized controlled trials. Am J Geriatr Psychiatry. 2015;23:1234–49.CrossRefPubMed
72.
Yang M, Xu D, Zhang Y, Liu X, Hoeven R, Cho W. A systematic review on natural medicines for the prevention and treatment of Alzheimer’s disease with meta-analyses of intervention effect of ginkgo. Am J Chin Med. 2014;42:505–21.CrossRefPubMed
73.
Yang G, Wang Y, Sun J, Zhang K, Liu J. Ginkgo biloba for mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. Curr Top Med Chem. 2016;16:520–8.CrossRefPubMed
74.
Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–14.CrossRefPubMed
75.
76.
77.
Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist a review of preclinical data. Neuropharmacology. 1999;38:735–67.CrossRefPubMed
78.
Olivares D, Deshpande VK, Shi Y, et al. N-Methyl d-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr Alzheimer Res. 2012;9:746–58.CrossRefPubMedPubMedCentral
79.
Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M. Effects of Ginko biloba supplementation in Alzheimer’s disease patients receiving cholinesterase inhibitors: data from the ICTUS study. Phytomedicine. 2014;21:888–92.CrossRefPubMed
Metadata
Title
Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer’s Disease: A Network Meta-Analysis
Authors
Onnita Thancharoen
Chulaporn Limwattananon
Onanong Waleekhachonloet
Thananan Rattanachotphanit
Phumtham Limwattananon
Panita Limpawattana
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 5/2019
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-019-00648-x

Other articles of this Issue 5/2019

Drugs & Aging 5/2019 Go to the issue

Leading Article

Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors

Original Research Article

Use of Medicines that May Exacerbate Heart Failure in Older Adults: Therapeutic Complexity of Multimorbidity

Review Article

Treatment of Patients with Advanced Gastroesophageal Adenocarcinoma: Does Age Matter?

Original Research Article

Modification of Potentially Inappropriate Prescribing Following Fall-Related Hospitalizations in Older Adults

Letter to the editor

The FORTA (Fit fOR The Aged) List 2018: Third Version of a Validated Clinical Tool for Improved Drug Treatment in Older People

Systematic Review

Effect of Vitamin B Supplementation on Cognitive Function in the Elderly: A Systematic Review and Meta-Analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits